|Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus|
|Li, J.1,2; An, L.3,4; Zhang, Z.1,3,4|
|关键词||systemic lupus erythematosus complement C3d C4d lymphocyte biomarker|
|刊名||CLINICAL AND EXPERIMENTAL RHEUMATOLOGY|
|WOS标题词||Science & Technology|
|关键词[WOS]||DISEASE-ACTIVITY ; REVISED CRITERIA ; 4TH COMPONENT ; C4D ; MARKER ; CLASSIFICATION ; EXACERBATIONS ; BIOMARKERS ; CHIDO ; C3D|
To evaluate the roles of complement activation products C3d and C4d binding to lymphocytes in the diagnosis of systemic lupus erythematosus (SLE) in a cohort of Chinese patients.
96 patients with SLE, 44 patients with other autoimmune disease and 40 healthy control individuals were enrolled in this study. The levels of C3d and C4d binding to peripheral CD4(+) T and CD19+ B lymphocyts (designated as T-C3d, T-C4d, B-C3d, B-C4d) was assessed by flow cytometry. The diagnostic values of these biomarkers were determined by receiver-operator characteristic analysis.
The levels of T-C3d, T-C4d, B-C3d, B-C4d were significantly higher in SLE patients than patients with other disease and healthy controls (p<0.01). As diagnostic tools, T-C4d and B-C4d were 61.1% sensitive 194.3% specific and 63.9% sensitive 194.3% specific in differentiating SLE patients from patients with other disease and healthy controls, respectively. T-C4d and B-C4d were significantly associated with SLE disease activity as measured by the SLE disease activity index (SLEDAI) (p<0.001), low serum C3 (p<0.001), low serum C4 (p=0.006), anti-dsDNA (IF) (p=0.001), and anti-dsDNA (ELISA) (p=0.001).
Complement activation products C3d and C4d binding to lymphocytes can reflect the disease activity of SLE and can be used as biomarkers for SLE.
|作者单位||1.Peking Univ, Hosp 1, Rheumatol & Clin Immunol Dept, Beijing 100034, Peoples R China|
2.Gen Hosp Tisco, Renal Dept, Taiyuan, Shanxi, Peoples R China
3.Peking Univ, Hosp 1, Dept Rheumatol, Beijing 100034, Peoples R China
4.Peking Univ, Hosp 1, Dept Clin Immunol, Beijing 100034, Peoples R China
|Li, J.,An, L.,Zhang, Z.. Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus[J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY,2014,32(1):48-53.|
|APA||Li, J.,An, L.,&Zhang, Z..(2014).Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus.CLINICAL AND EXPERIMENTAL RHEUMATOLOGY,32(1),48-53.|
|MLA||Li, J.,et al."Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus".CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 32.1(2014):48-53.|